# Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug

> **NCT06391736** · PHASE1,PHASE2 · RECRUITING · sponsor: **GeneCradle Inc** · enrollment: 33 (estimated)

## Conditions studied

- Pompe Disease (Late-onset)

## Interventions

- **GENETIC:** GC301

## Key facts

- **NCT ID:** NCT06391736
- **Lead sponsor:** GeneCradle Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-19
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06391736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06391736, "Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06391736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*